Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

459.81 -3.46 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 975,147
Open 467.00
Bid (Size) 448.52 (1)
Ask (Size) 485.25 (1)
Prev. Close 463.27
Today's Range 458.14 - 467.00
52wk Range 377.85 - 519.88
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
3 Cash-Burning Stocks Walking a Fine Line
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
Via StockStory
Topics Bankruptcy Economy

Performance

YTD
+13.3%
+13.3%
1 Month
+4.0%
+4.0%
3 Month
-6.0%
-6.0%
6 Month
+10.3%
+10.3%
1 Year
-5.8%
-5.8%

More News

Read More
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
My 3 Top Stocks to Buy in a Market That's Highly Volatile (Again)
Via The Motley Fool
Topics Artificial Intelligence Energy World Trade
The Best Stocks to Invest $1,000 in Right Now
Via The Motley Fool
Topics Artificial Intelligence
10 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
Via The Motley Fool
Motley Fool Co-Founder David Gardner Reviews Stock Picks
Via The Motley Fool
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via FinancialNewsMedia
Topics Death
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz
Via The Motley Fool
Topics Stocks
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via FinancialNewsMedia
Topics Death
3 No-Brainer Stocks to Buy in July
Via The Motley Fool
The Best Stocks to Invest $1,000 In Right Now
Via The Motley Fool
Topics Artificial Intelligence Government
Vertex Pharma’s New Cystic Fibrosis Drug Granted Approval By EU
Via Stocktwits
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Via Benzinga
How Do Investors Really Feel About Vertex Pharmaceuticals?
Via Benzinga
3 S&P 500 Stocks with Mounting Challenges
Via StockStory
Topics Artificial Intelligence Stocks
Vertex Pharmaceuticals Unusual Options Activity
Via Benzinga
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Unpopular Stocks Facing Headwinds
Via StockStory
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
Via Benzinga
Friday's session: gap up and gap down stock in the S&P500 index
Via Chartmill
2 Growth Stocks to Buy and Hold for 10 Years
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade

Frequently Asked Questions

Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 459.81
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 07/18/25 04:00 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 119.29B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 119B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.